UCLA logoIntegrated Substance Abuse Programs

UCLA Integrated Substance Abuse Programs

Researchers' Profiles

Larissa Mooney, M.D.

Larissa Mooney, M.D.

Principal Investigator, Greater Southern California Node, NIDA CTN
Professor, Dept. Of Psychiatry And Biobehavioral Sciences
Director, Addiction Psychiatry Division
Geffen School Of Medicine at UCLA

Larissa Mooney, M.D., is a Professor of Clinical Psychiatry and Director of the Addiction Psychiatry Division in the Department of Psychiatry and Biobehavioral Sciences at UCLA. She directs the UCLA Addiction Psychiatry Clinic and the UCLA-Veterans Affairs (VA) Addiction Psychiatry Fellowship Program, where she teaches psychiatrists being trained in the clinical management of substance use disorders (SUDs) and mental health disorders. Dr. Mooney previously served as the Section Chief for Substance Use Disorders at the Greater Los Angeles VA. She is the President of the American Academy of Addiction Psychiatry (AAAP), a Distinguished Fellow of the American Psychiatric Association (APA), and a fellow of the American Society of Addiction Medicine (ASAM). Dr. Mooney has conducted clinical research at UCLA Integrated Substance Abuse Programs (ISAP) on pharmacological and behavioral treatment interventions for SUDs and co-occurring substance use and mental health disorders. She is one of two Principal Investigators for the Greater Southern California Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN). She has NIDA funding to study functional outcomes associated with cannabis use reduction and treatment interventions for opioid use disorder and stimulant use disorder.

  • Undergraduate: Cornell University, NY, B.S., Biology, 1997
  • Medical School: SUNY Health Science Center at Brooklyn, NY, M.D., 2001
  • Residency: New York University, NY, Psychiatry, 2005
  • Fellowship: Cedars-Sinai Medical Center, CA, Addiction, 2006
  • Addiction Psychiatry
  • Co-occurring substance use and mental health disorders

760 Westwood Plaza, Suite 37-420
Los Angeles, CA 90095
Ph (310) 267-5419
LMooney@mednet.ucla.edu

Hser, Y. I., Mooney, L. J., Baldwin, L. M., Ober, A., Marsch, L. A., Sherman, S., Matthews, A., Clingan, S., Fei, Z., Zhu, Y., Dopp, A., Curtis, M. E., Osterhage, K. P., Hichborn, E. G., Lin, C., Black, M., Calhoun, S., Holtzer, C. C., Nesin, N., Bouchard, D., Saxon, A. J. (2023). Care coordination between rural primary care and telemedicine to expand medication treatment for opioid use disorder: Results from a single-arm, multisite feasibility study. The Journal of Rural Health, 10.1111/jrh.12760. Advance online publication. https://doi.org/10.1111/jrh.12760

Lin, C., Pham, H., Zhu, Y., Clingan, S. E., Lin, L. A., Murphy, S. M., Campbell, C. I., Sorrell, T. R., Liu, Y., Mooney, L. J., & Hser, Y. I. (2023). Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. Drug and alcohol dependence, 242, 109711. https://doi.org/10.1016/j.drugalcdep.2022.109711

Baskerville, W. A., Grodin, E. N., Lin, J., Miotto, K., Mooney, L. J., & Ray, L. A. (2023). Alcohol Use Among Treatment-Seeking Individuals with Opioid Use Disorder. Journal of Studies on Alcohol and Drugs, 10.15288/jsad.22-00176. Advance online publication. https://doi.org/10.15288/jsad.22-00176

Mooney L. J. (2022). Medication Treatment for Opioid Use Disorder Reduces Suicide Risk. The American Journal of Psychiatry, 179(4), 262–263. https://doi.org/10.1176/appi.ajp.20220173

Zhu, Y., Fei, Z., Mooney, L. J., Huang, K., & Hser, Y. I. (2022). Social Determinants of Mortality of COVID-19 and Opioid Overdose in American Rural and Urban Counties. Journal of Addiction Medicine, 16(1), e52–e55. https://doi.org/10.1097/ADM.0000000000000834

Mooney, L. J., Zhu, Y., Yoo, C. K., Wolitzky-Taylor, K., & Hser, Y. I. (2022). Association Between Benzodiazepine and Opioid Prescription and Mortality Among Patients in a Large Healthcare System. Journal of Addiction Medicine, 16(1), 65–71. https://doi.org/10.1097/ADM.0000000000000828

Hser, Y. I., Zhu, Y., Fei, Z., Mooney, L. J., Evans, E. A., Kelleghan, A., Matthews, A., Yoo, C., & Saxon, A. J. (2022). Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction (Abingdon, England), 117(1), 151–161. https://doi.org/10.1111/add.15594

Salem, B. A., Gonzales-Castaneda, R., Ang, A., Rawson, R. A., Dickerson, D., Chudzynski, J., Penate, J., Dolezal, B., Cooper, C. B., & Mooney, L.J. (2022). Craving among individuals with stimulant use disorder in residential social model-based treatment - Can exercise help?. Drug and Alcohol Dependence, 231, 109247. https://doi.org/10.1016/j.drugalcdep.2021.109247

Zhu, Y., Mooney, L. J., Yoo, C., Evans, E. A., Kelleghan, A., Saxon, A. J., Curtis, M. E., & Hser, Y. I. (2021). Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug and Alcohol Dependence, 228, 108996. https://doi.org/10.1016/j.drugalcdep.2021.108996

Mooney, L. J. (2019). The Assessment and Treatment of Addiction: Best Practices and New Frontiers. Elselvier, Inc. https://doi.org/10.1016/C2016-0-05129-X

Liao, J. Y., Mooney, L. J., Zhu, Y., Valdez, J., Yoo, C., & Hser, Y. I. (2019). Relationships between marijuana use, severity of marijuana-related problems, and health-related quality of life. Psychiatry Research, 279, 237–243. https://doi.org/10.1016/j.psychres.2019.03.010

Mooney, L. J., Zhu, Y., Yoo, C., Valdez, J., Moino, K., Liao, J. Y., & Hser, Y. I. (2018). Reduction in Cannabis Use and Functional Status in Physical Health, Mental Health, and Cognition. Journal of Neuroimmune Pharmacology, 13(4), 479–487. https://doi.org/10.1007/s11481-018-9813-6

Zhu, Y., Evans, E. A., Mooney, L. J., Saxon, A. J., Kelleghan, A., Yoo, C., & Hser, Y. I. (2018). Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. Journal of Neuroimmune Pharmacology, 13(4), 488–497. https://doi.org/10.1007/s11481-018-9801-x

Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., Chang, L., Walker, R., Trivedi, M., Croteau, D., Sparenborg, S., & Ling, W. (2016). Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. Journal of Addiction Medicine, 10(4), 236–243. https://doi.org/10.1097/ADM.0000000000000218

Mooney, L. J., Cooper, C., London, E. D., Chudzynski, J., Dolezal, B., Dickerson, D., Brecht, M. L., Peñate, J., & Rawson, R. A. (2014). Exercise for methamphetamine dependence: rationale, design, and methodology. Contemporary Clinical Trials, 37(1), 139–147. https://doi.org/10.1016/j.cct.2013.11.010

Mooney, L. J., Nielsen, S., Saxon, A., Hillhouse, M., Thomas, C., Hasson, A., Stablein, D., McCormack, J., Lindblad, R., & Ling, W. (2013). Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. Contemporary Clinical Trials, 34(2), 196–204. https://doi.org/10.1016/j.cct.2012.11.002